CARPRODYL F 50 MG, TABLETS FOR DOGS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

CARPROFEN

Available from:

Ceva Santé Animale

ATC code:

QM01AE91

INN (International Name):

CARPROFEN

Dosage:

50 Milligram

Pharmaceutical form:

Tablets

Prescription type:

POM

Therapeutic group:

Canine

Therapeutic area:

Carprofen

Therapeutic indications:

N.S.A.I.D

Authorization status:

Authorised

Authorization date:

2008-07-25

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprodyl F 50 mg, tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
Active ingredient:
Carprofen
50 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
Circular, beige, scored tablets
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease.
As a follow up to parenteral analgesia in the management of post-operative pain
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in case of known hypersensitivity to active substance or to any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal
ulceration or bleeding, or where there is evidence of a blood dyscrasia.
Do not use in pups less than 4 months of age.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 21/06/2013_
_CRN 7013105_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with
bacterial infectio
                                
                                Read the complete document
                                
                            

Search alerts related to this product